-
1.发明公开
公开(公告)号：EP4338751A3
公开(公告)日：2024-05-22
申请号：EP24153812.3
申请日：2018-12-20
IPC分类号： A61K31/558 , A61K31/335 , A61K31/472 , A61K31/551 , A61K45/00 , A61P9/12 , A61P27/02 , A61P27/06 , A61P43/00 , A61K31/55 , A61K45/06
CPC分类号： A61K31/472 , A61K31/551 , A61P27/06 , A61K45/06 , A61K31/55
摘要： An object of the present invention is to find out a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension.
By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.-
公开(公告)号：EP4289446A3
公开(公告)日：2024-01-10
申请号：EP23202597.3
申请日：2009-05-28
IPC分类号： A61K9/08 , A61K31/5575 , A61K47/10 , A61K47/26 , A61K47/18
摘要： The present invention relates to a method for increasing aqueous solubility and improving stability of tafluprost in an aqueous ophthalmic solution, comprising the steps of preparing an aqueous ophthalmic solution containing 0.0010-0.0025% tafluprost, 0.075% polysorbate 80, 0.005-0.2% stabilizing agent and substantially no preservatives, and packaging the preservative-free ophthalmic solution in a container consisting essentially of polyethylene.
-
公开(公告)号：EP4230210A1
公开(公告)日：2023-08-23
申请号：EP21880135.5
申请日：2021-10-13
发明人： ENDO, Yoko , MASAKI, Kenji
摘要： The present invention provides a stable pharmaceutical composition comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof and a method of stabilizing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.
-
4.发明公开
公开(公告)号：EP3932488A1
公开(公告)日：2022-01-05
申请号：EP20763542.6
申请日：2020-02-26
摘要： Provided is an ophthalmic composition comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. Also provided is an agent for prevention or treatment of dry eyes, comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. These solution-type aqueous eye drop for treatment of dry eye each comprises diquafosol sodium with a concentration of 3%(w/v), hydroxyethyl cellulose and polyvinylpyrrolidone having a K value of 30, and is characterized in that a single dose of 1 to 2 drops is administered by eye drop three times per day.
-
公开(公告)号：EP3915528A1
公开(公告)日：2021-12-01
申请号：EP20745911.6
申请日：2020-01-23
发明人： KAMIKATANO, Mitsuru , OKABE, Komei , KOYAMA, Yukie , OHASHI, Koji
摘要： To prove an optical probe that can illuminate an entire desired region at one time, even in a narrow space. An optical probe including: a linear light guide to guide light from a light source device; a planar emitter to be connected to a tip portion of the linear light guide, to emit the light; a reflective surface provided in a part of the planar emitter, to reflect the light having entered the planar emitter; and an emitting surface provided so as to face the reflective surface, to allow the light reflected by the reflective surface to be emitted from a region of the reflective surface.
-
公开(公告)号：EP3900728A1
公开(公告)日：2021-10-27
申请号：EP19899899.9
申请日：2019-12-17
发明人： KATO, Masatomo , ODA, Tomoko , KIDO, Kazutaka
IPC分类号： A61K31/575 , A61P27/02 , A61P27/10 , A61K9/06 , A61K9/08
摘要： The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：EP3900714A1
公开(公告)日：2021-10-27
申请号：EP19897644.1
申请日：2019-12-17
发明人： KATO, Masatomo , ODA, Tomoko , NOZAKI, Kensuke
摘要： The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：EP3730143A1
公开(公告)日：2020-10-28
申请号：EP18890141.7
申请日：2018-12-20
发明人： FUWA Masahiro , TANIGUCHI Takazumi
IPC分类号： A61K31/551 , A61K31/444 , A61K31/472 , A61P27/02 , A61P27/06 , A61P43/00
摘要： An object of the present invention is to find out a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension.
By combining omidenepag and ripasudil or netarsudil, each complement and/or enhances the intraocular pressure lowering effect. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.-
公开(公告)号：EP3714877A1
公开(公告)日：2020-09-30
申请号：EP20164602.3
申请日：2009-05-28
IPC分类号： A61K9/08 , A61K47/10 , A61K47/26 , A61K47/18 , A61K31/5575
摘要： The present invention relates to a preservative-free ophthalmic aqueous composition containing prostaglandin (PG hereafter) F2α analogues for treating ocular hypertension and glaucoma.
-
公开(公告)号：EP3442623A1
公开(公告)日：2019-02-20
申请号：EP17782891.0
申请日：2017-04-07
发明人： SHETTY, Gautam, N. , CASTAGNA, Lou
-
-
-
-
-
-
-
-
-
搜索结果
454 条记录 (耗时 0.021 秒)
